Fig. 3
From: Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
The prolonged platinum-free interval. a The time interval between the date of the last first-line platinum-based chemotherapy treatment and the date of changing to other therapies after PLD. b The proportion of patients changing to other therapies over time (from the date of enrollment)